

DAFTAR PUSTAKA

1. Majumdar D, Bebb J. Helicobacter pylori infection and peptic ulcers. *Med (United Kingdom)*. 2019;47(5):292–300.
2. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. *Clin Microbiol Rev*. 2007;20(2):280–322.
3. Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. *Biomed J [Internet]*. 2016;39(1):14–23. Available from: <http://dx.doi.org/10.1016/j.bj.2015.06.002>
4. Hooi JK, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. *Gastroenterology [Internet]*. 2017;153(2):420–9. Available from: <http://dx.doi.org/10.1053/j.gastro.2017.04.022>
5. Hu Y, Zhu Y, Lu NH. Novel and effective therapeutic regimens for helicobacter pylori in an era of increasing antibiotic resistance. *Front Cell Infect Microbiol*. 2017;7(MAY):1–20.
6. World Health Organization. Worldwide country situation analysis : Worldwide country situation analysis : World Heal Organ 20 Ave Appia, 1211 Geneva 27, Switz [Internet]. 2015;(April):1–50. Available from: <http://www.who.int/drugresistance/en/ISBN9789241564946%0Ahttp://www.who.int/drugresistance/documents/situationanalysis/en/>
7. Asoso OS, Akharaiyi FC, Animba LS. Antibacterial activities of plantain (*Musa paradisiaca*) peel and fruit. *Der Pharm Lett*. 2016;8(5):5–11.
8. Pratama HY, Ernawati, Mahmud NRA. Uji Antibakteri Ekstrak Kulit Buah Pisang Kepok (*Musa paradisiaca x balbisiana*) Mentah Terhadap Pertumbuhan Bakteri *Staphylococcus aureus* Antibacterial Teest of *Musa paradisiaca x balbisiana* Peel Extract against the Growth of *Staphylococcus aureus*. *J Sainsmat [Internet]*. 2018;7(2):147–52. Available from: <http://ojs.unm.ac.id/index.php/sainsmat>
9. Wardini LA, Sulandjari S. Pengaruh Penambahan Tepung Kulit Pisang Kepok Dan Kulit Jeruk Nipis Terhadap Hasil Lulur Tradisional. 2017;6(1):73–80.
10. Septiani S, Dewi EN, Wijayanti I. AKTIVITAS ANTIBAKTERI EKSTRAK LAMUN (*Cymodocea rotundata*) TERHADAP BAKTERI *Staphylococcus aureus* DAN *Escherichia coli* (Antibacterial Activities of Seagrass Extracts (*Cymodocea rotundata*) Against *Staphylococcus aureus* and *Escherichia coli*). *SAINTEK Perikan Indones J Fish Sci Technol*. 2017;13(1):1.
11. Ariani N, Riski A. Aktivitas Ekstrak Etanol Kulit Buah Pisang Kepok Mentah (*Musa paradisiaca forma typica*) Terhadap Pertumbuhan Candida

- albicans Secara In Vitro. *J Pharmascience*. 2018;5(1):39–44.
12. Ngajow M, Abidjulu J, Kamu VS. Pengaruh Antibakteri Ekstrak Kulit Batang Matoa (*Pometia pinnata*) terhadap Bakteri *Staphylococcus aureus* secara In vitro. *J MIPA*. 2013;2(2):128.
 13. Moore K, Dally A, Agur A. Moore: Clinically Oriented Anatomy 7th Ed. Philadelphia: Lippincott Williams and Wilkins. 2014. 230–231 p.
 14. Drake R, Vogl A, Mitchell A. Gray's Basic Anatomy. 2012. 153–154 p.
 15. Eroschenko VP. diFiore's Atlas of Histology with Functional Correlations 11th Edition. Lippincott Wiliams & Walkins; 2007.
 16. Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, Russo VM, et al. Gastritis: The histology report. *Dig Liver Dis*. 2011;43(SUPPL. 4).
 17. Nisa S. Gastritis (Warm-e-medra): A review with Unani approach. *Int J Adv Sci Res*. 2018;43(October):43–5.
 18. Novitasary A, sabilu Y, Ismail C. Faktor Determinan Gastritis Klinis Pada Mahasiswa Di Fakultas Kesehatan Masyarakat Universitas Halu Oleo Tahun 2016. *J Ilm Mhs Kesehat Masy Unsyiah*. 2017;2(6):183949.
 19. Sipponen P, Maaroos HI. Chronic gastritis. *Scand J Gastroenterol*. 2015;50(6):657–67.
 20. Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clin Microbiol Rev*. 2006;19(3):449–90.
 21. Azer SA, Akhondi H. Gastritis. StatPearls Publishing; 2020.
 22. Marshall BJ. *Helicobacter pylori* [Internet]. ITIS Report. [cited 2021 Mar 29]. Available from: https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=962224#null
 23. Krzyzek P, Gościński G. Morphology of *Helicobacter pylori* as a result of peptidoglycan and cytoskeleton rearrangements. *Prz Gastroenterol*. 2018;13(3):182–95.
 24. Dunn BE, Cohen H, Blaser MJ. *Helicobacter pylori*. *Clin Microbiol Rev Am Soc Microbiol*. 1997;
 25. Ansari S, Yamaoka Y. *Helicobacter pylori* Virulence factors Exploiting Gastric Colonization and its Pathogenicity. 2019;
 26. Shin JM, Sachs G. Pharmacology of proton pump inhibitors (PPIs). 2016;
 27. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. *J Neurogastroenterol Motil*. 2013;19(1):25–35.
 28. Sugiyama T. Proton pump inhibitors: Key ingredients in helicobacter pylori eradication treatment. *Front Gastrointest Res*. 2013;32(1):59–67.
 29. Young A, Kumar MA, Thota PN. GERD: A practical approach. *Cleve Clin J Med*. 2020;87(4):223–30.

30. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: An update. *Am Fam Physician*. 2002;66(2):273–80.
31. Dewi S, Laksmi PW, Syam AF, Dewiasty E, Seto E. Pengaruh Penggunaan Proton Pump Inhibitor Jangka Panjang terhadap Sindrom Frailty pada Pasien Usia Lanjut. *J Penyakit Dalam Indones*. 2016;3(3):143.
32. Lin H-J. Role of proton pump inhibitors in the management of peptic ulcer bleeding. *World J Gastrointest Pharmacol Ther*. 2010;1(2):51.
33. Kuipers EJ. PPIs for prevention and treatment of peptic ulcer. *Lancet Gastroenterol Hepatol* [Internet]. 2018;3(4):214–5. Available from: [http://dx.doi.org/10.1016/S2468-1253\(18\)30047-5](http://dx.doi.org/10.1016/S2468-1253(18)30047-5)
34. Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. *J Neurogastroenterol Motil*. 2018;24(2):182–96.
35. Fosmark R, Martinsen TC, Waldum HL. Adverse Effects of Proton Pump Inhibitors — Evidence and Plausibility. 2019;
36. You CH, Lin CK, Chen PH, Park S, Chen YY, Khan N, et al. Clarithromycin use and the risk of mortality and cardiovascular events: A systematic review and meta-analysis. *PLoS One*. 2019;14(12):1–13.
37. LeBel M. Pharmacokinetic Properties of Clarithromycin: A Comparison with Erythromycin and Azithromycin. *Can J Infect Dis*. 1993;4(3):148–52.
38. Laboratories A. BIAXIN ® Filmtab ® (clarithromycin tablets , USP) BIAXIN ® XL Filmtab ® (clarithromycin extended-release tablets) BIAXIN ® Granules (clarithromycin for oral suspension , USP). 2012;(10). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050662s044s050,50698s026s030,050775s015s019lbl.pdf
39. Grumezescu AM. Fabrication and Self-Assembly of Nanobiomaterials Applications of Nanobiomaterials. Volume 1. Copyright © 2016 Elsevier Inc. All rights reserved.;
40. Robertson BD. Tuberculosis. Vol. 88. Elsevier; 2008. 92–95 p.
41. van Bambeke F, Mingeot-Leclercq M-P, Glupezynski Y, Tulkens PM. Mechanisms of Action. *Infect Dis (Auckl)*. 2017;1162-1180.e1.
42. Vázquez-Laslop N, Mankin AS. How Macrolide Antibiotics Work. *Trends Biochem Sci* [Internet]. 2018;43(9):668–84. Available from: <https://doi.org/10.1016/j.tibs.2018.06.011>
43. Peters DH, Clissold SP. Clarithromycin: A Review of its Antimicrobial Activity, Pharmacokinetic Properties and Therapeutic Potential. *Drugs*. 1992;44(1):117–64.
44. Castle SS, Medical VA. Amoxicillin. 2007;2333(1).
45. National Center for Biotechnology Information. PubChem Compound Summary for CID 33613, Amoxicillin. [Internet]. [cited 2021 Mar 28].

- Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Amoxicillin>
46. Agent A, Castle SS. Amoxicillin Amoxicillin From Conventional Prodrugs to Pro-drugs Designed by Molecular Orbital Methods Supported Liquid Membranes in Pharmaceutics and Biotechnology. 2015;
 47. Bobak J A, Niloufar RK, Praveen V. Amoxicillin. StatPearls Publishing; 2020.
 48. Anwar AF, Azis AA. Efektifitas Ekstrak Pektin dari Kulit Buah Pisang Kepok (*Musa paradisiaca Formatypica*) Sebagai Antimikroba. Bionature. 2019;19(2):95–104.
 49. Vilhena R de O, Marson BM, Budel JM, Amano E, Messias-Reason IJ de T, Pontarolo R. Morpho-anatomy of the inflorescence of *Musa × paradisiaca*. Rev Bras Farmacogn [Internet]. 2019;29(2):147–51. Available from: <https://doi.org/10.1016/j.bjp.2019.01.003>
 50. *Musa X paradisiaca L. (pro sp.)* [Internet]. ITIS Report. [cited 2021 Apr 8]. Available from: https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=42391&print_version=SCR&source=from_print#null
 51. Ulfa A, Ekastuti DR, Wresdiyati T. Potensi Ekstrak Kulit Pisang Kepok (*Musa paradisiaca forma typica*) dan Uli (*Musa paradisiaca sapientum*) Menaikkan Aktivitas Superoksida Dismutase dan Menurunkan Kadar Malondialdehid Organ Hati Tikus Model Hipercolesterolemia. Acta Vet Indones. 2020;8(1):40–6.
 52. Sapara TU, Waworuntu O. Efektivitas Antibakteri Ekstrak Daun Pacar Air (*Impatiens Balsamina L.*) Terhadap Pertumbuhan *Porphyromonas Gingivalis*. Pharmacon. 2016;5(4):10–7.
 53. Dey P, Kundu A, Kumar A, Gupta M, Lee BM, Bhakta T, et al. Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids) [Internet]. Recent Advances in Natural Products Analysis. Elsevier Inc.; 2020. 505–567 p. Available from: <http://dx.doi.org/10.1016/B978-0-12-816455-6.00015-9>
 54. Cushnie TPT, Cushnie B, Lamb AJ. Alkaloids: An overview of their antibacterial, antibiotic-enhancing and antivirulence activities. Int J Antimicrob Agents [Internet]. 2014;44(5):377–86. Available from: <http://dx.doi.org/10.1016/j.ijantimicag.2014.06.001>
 55. Amalia A, Sari I, Nursanty R. Aktivitas antibakteri ekstrak etil asetat daun sembung terhadap bakteri MRSA. Pros Semin Nas Botik. 2017;387–91.
 56. Redha A. Flavonoid: Struktur, Sifat Antioksidatif dan Perannya Dalam Sistem Biologis. J Berlin. 2010;9(2):196–202.
 57. Cushnie TPT, Lamb AJ. Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Agents. 2011;38(2):99–107.
 58. . Y, Purnamaningsih H, Nururrozi A, Indarjulianto S. Saponin : Dampak

- terhadap Ternak (Ulasan). J Peternak Sriwij. 2017;6(2):79–90.
59. Sudarmi K, Darmayasa IBG, Muksin IK. UJI FITOKIMIA DAN DAYA HAMBAT EKSTRAK DAUN JUWET (*Syzygium cumini*) TERHADAP PERTUMBUHAN *Escherichia coli* DAN *Staphylococcus aureus* ATCC. SIMBIOSIS J Biol Sci. 2017;5(2):47.
60. Varghese N, Joy PP. Naveena Varghese. 2016;(August).
61. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests: Approved standard - Eleventh edition. Vol. 32. 2012. 1–58 p.
62. Piccolomini R, Di Bonaventura G, Catamo G, Carbone F, Neri M. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of *Helicobacter pylori* strains to 20 antimicrobial agents. J Clin Microbiol. 1997;35(7):1842–6.
63. Wahyuni N, Rita W, Asih I. Aktivitas Antibakteri Ekstrak Kulit Pisang Kepok Kuning (*Musa paradisiaca L.*) Terhadap Bakteri *Staphylococcus aureus* DAN *Escherichia coli* Serta Penentuan Total Flavonodi dan Fenol Dalam Fraksi Aktif. J Kim. 2019;13(1):9.
64. Ariani N, Niah R. Uji Aktivitas Antibakteri Ekstrak Etanol Kulit Pisang Kepok Mentah Secara in Vitro. J Ilm Manuntung. 2020;5(2):161.
65. Egra S, Mardhiana ., Rofin M, Adiwena M, Jannah N, Kuspradini H, et al. Aktivitas Antimikroba Ekstrak Bakau (*Rhizophora mucronata*) dalam Menghambat Pertumbuhan *Ralstonia Solanacearum* Penyebab Penyakit Layu. Agrovigor J Agroekoteknologi. 2019;12(1):26.